Goodbody Health share price, company news, analysis and interviews

Goodbody Health (AQSE: GDBY) has announced that Marc Howells has resigned from the Board as Chief Executive Officer, with immediate effect.  The Company wishes to thank Marc for his contribution to the Company. George Thomas, an existing Executive Director of Goodbody Health and Managing Director of Goodbody Wellness has been appointed as the new Chief Executive Officer, also with immediate effect. Geremy Thomas, Goodbody Health Executive Chairman, said: “We are very pleased to develop the business further under the guidance of George who has successfully led the clinic business for over two years.” The Directors of the Company accept responsibility for the contents

Goodbody Health (AQSE: GDBY) has today announced that it has signed an agreement with Allied Pharmacies Limited to join the Goodbody clinic network. The new Allied Pharmacies clinics adds 17 pharmacies that can provide a range of services including the range of diagnostic testing offered by the Goodbody clinics and other health services including ear wax micro suction.  Earwax removal is no longer offered by most GPs, so patients are increasingly turning to community pharmacies for advice and treatment. 2.3 million people a year in the UK experience build-up of earwax that requires removal, according to the National Institute of Health and

Goodbody Health (AQSE:GDBY) has announced that it has signed a contract with Tasso Inc, the leading provider of convenient, clinical grade blood collection solutions, for the UK pharmacy and wellness market. Tasso produces a signature line of virtually painless medical devices to draw a capillary blood sample with no needles and without the need for a phlebotomist, which can then be sent to an accredited laboratory for analysis using a compatible sample collection reservoir. This will allow more Goodbody Health clinics and wellness locations as well as other healthcare professionals to undertake the tests requiring more blood than is delivered through the

Goodbody Health Inc. (AQSE: GDBY) has announced its half year 2022 unaudited Interim Financial Statements for the six months to 30 June 2022. The revenue at £7.40m was £2.55m higher than the comparative period in 2021. As anticipated, the quarter was lower than Q1 due to the expected decline in COVID testing. Non-Covid testing continues to be rolled out to improve revenue by the end of 2022. The Company continues to deliver PCR testing and lateral flow tests based on travel requirements.  Alternative testing is a lifestyle choice which is growing but will obviously lag regulated testing. As at today, we have